At week 12 , patients receiving brodalumab were randomly assigned again to receive a brodalumab maintenance dose of 210 mg every 2 weeks or 140 mg every 2 weeks , every 4 weeks , or every 8 weeks ; patients receiving ustekinumab continued to receive ustekinumab every 12 weeks , and patients receiving placebo received 210 mg of brodalumab every 2 weeks .